Drug Profile
Research programme: acute pain therapeutics - New River Pharmaceuticals
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator New River Pharmaceuticals
- Class Morphine derivatives
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute pain
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 21 Feb 2008 Discontinued - Preclinical for Acute pain in USA (PO)
- 12 Aug 2005 New River Pharmaceuticals initiates clinical trials of NRP 290 for acute pain in the USA